CPC A61K 39/04 (2013.01) [A61K 35/15 (2013.01); A61K 39/00114 (2018.08); A61K 39/001119 (2018.08); A61K 39/39 (2013.01); A61K 2039/515 (2013.01); A61K 2039/585 (2013.01)] | 17 Claims |
1. A vaccine composition comprising:
1) immunotherapeutic primed antigen presenting cells, wherein the antigen presenting cells are isolated from a urine sample or bladder mucosa of an immunotherapeutic treated subject; and
2) an IL-15:IL-15Rα fusion protein complex, wherein the antigen presenting cells are exposed ex-vivo to the IL-15:IL-15Rα fusion protein complex.
|